Vitti Long Haul

Vitti Long Haul focuses on researching innovative therapies for people experiencing long-term effects of COVID-19, including pulmonary fibrosis. Its investigational treatments, VL-PX10 and VL-P22, combine mesenchymal stem cells, exosomes, and biomaterials and are being evaluated in Phase 2 human clinical trials. The company also offers a physician-led Expanded Access Program for eligible patients. Through scientific research and patient education, it aims to advance understanding of emerging treatment approaches and support patients and healthcare professionals seeking information about clinical research.